Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03061539
Title Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors University College, London
Indications

prostate adenocarcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.